Search research articles
Contact Us
Filters
Showing results (211-220 of 237) with videos related to
Page
of 24
Sort By:
Molecular Cancer Research : MCR
|
October 21, 2021
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress
Mary M Mullen, Elena Lomonosova, Michael D Toboni, et al.
International Journal of Cancer
|
October 25, 2017
Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study
A S Felix, T M Brasky, D E Cohn, et al.
Gynecologic Oncology
|
March 5, 2019
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study
Rebecca A Brooks, David S Tritchler, Kathleen M Darcy, et al.
Communications Biology
|
July 3, 2023
Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival
Emilee N Kotnik, Mary M Mullen, Nicholas C Spies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
American Journal of Obstetrics and Gynecology
|
August 11, 2018
Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study
Ashley S Felix, David E Cohn, Theodore M Brasky, et al.
Biorxiv : the Preprint Server for Biology
|
October 3, 2025
Targeting RAD52 overcomes PARP inhibitor resistance in preclinical <i>Brca2</i>-deficient ovarian cancer model
Yukihide Ota, Vijayalaxmi Gupta, Bisiayo E Fashemi, et al.
Gynecologic Oncology
|
February 22, 2025
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
Paulina J Haight, Marilyn Sanchez, Samantha M Thomas, et al.
Gynecologic Oncology
|
September 4, 2025
Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol
Koji Matsuo, Danielle M Enserro, Jason D Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Charles N Landen, Luciana Molinero, Habib Hamidi, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 237) with videos related to
Sort By:
Page
of 24
Molecular Cancer Research : MCR
|
October 21, 2021
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress
Mary M Mullen, Elena Lomonosova, Michael D Toboni, et al.
International Journal of Cancer
|
October 25, 2017
Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study
A S Felix, T M Brasky, D E Cohn, et al.
Gynecologic Oncology
|
March 5, 2019
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study
Rebecca A Brooks, David S Tritchler, Kathleen M Darcy, et al.
Communications Biology
|
July 3, 2023
Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival
Emilee N Kotnik, Mary M Mullen, Nicholas C Spies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
American Journal of Obstetrics and Gynecology
|
August 11, 2018
Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study
Ashley S Felix, David E Cohn, Theodore M Brasky, et al.
Biorxiv : the Preprint Server for Biology
|
October 3, 2025
Targeting RAD52 overcomes PARP inhibitor resistance in preclinical <i>Brca2</i>-deficient ovarian cancer model
Yukihide Ota, Vijayalaxmi Gupta, Bisiayo E Fashemi, et al.
Gynecologic Oncology
|
February 22, 2025
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
Paulina J Haight, Marilyn Sanchez, Samantha M Thomas, et al.
Gynecologic Oncology
|
September 4, 2025
Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol
Koji Matsuo, Danielle M Enserro, Jason D Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Charles N Landen, Luciana Molinero, Habib Hamidi, et al.
Page
of 24